Denis Alibec, the FCSB forward who rejoined the club this summer, suffered an injury just nine minutes into the Supercup clash against CFR Cluj, forcing an early substitution. Initial diagnosis suggested a possible collateral ligament injury, but the first MRI scan performed on July 7 yielded inconclusive results, prompting the club to seek multiple specialist opinions for a definitive diagnosis.
FCSB’s leadership, including club owner Gigi Becali, has expressed patience while awaiting clarity on Alibec’s condition. Becali confirmed that the club will hold off on any decisions until further medical evaluations are completed, including a repeat MRI after a 10-day rest period during which Alibec has been removed from all training to prevent aggravation of the injury.
The uncertainty surrounding Alibec’s injury is significant given the timing. He is expected to miss at least the next two weeks, which encompasses critical fixtures: the first Champions League qualifying round against Inter Club d’Escaldes, Liga I matches against Hermannstadt and Petrolul, and the second qualifying round of the Champions League versus either TNS or Shkendija. Should the injury prove more severe, with ligament damage confirmed, Alibec’s absence could extend to around 45 days, potentially ruling him out of early domestic derbies and the crucial European play-off phase.
The 34-year-old striker, valued at approximately €600,000 according to Transfermarkt, had high expectations placed on him as a summer signing aiming to bolster FCSB’s attack. His early injury setback complicates coach Elias Charalambous’s plans, who will need to adjust tactics and squad selection in key upcoming matches.
This injury episode highlights both the fragility of squad depth at FCSB and the challenges the club faces in maintaining competitive momentum across multiple competitions at the start of the season. The medical team’s cautious approach underscores the importance of ensuring Alibec’s full recovery to avoid jeopardizing his availability for the season’s decisive phases.